SCIENTIFIC ADVISORY BOARD
This board consists of international experts of translational and clinical research of STS.
Prof. Judith Bovee
Clinician scientist
Professor Pathology (bone and soft tissue tumors)
Leiden University Medical Center
Netherlands
Prof. Robert Maki
Medical Oncologist (Sarcoma)
Early Drug Development Specialist
Memorial Sloan-Kettering Cancer Center
New-York, USA
Pedro Romero, MD
Director of Translational Medicine
NOVIGENIX
Switzerland
Univ.-Prof. Zlatko Trajanoski
Professor for Bioinformatics,
Head of the Institute of Bioinformatics at the Biocenter,
Medical University of Innsbruck
Austria
Prof. Dr. Jakob N. Kather, MSc
Professor of Clinical Artificial Intelligence Else Kröner Fresenius Center for Digital Health
Technical University Dresden
Germany
————————————————————
EXECUTIVE COMMITEE
This board consists of the Scientific Coordinator, workpackage and partners’ scientific leaders.
Objectives: Main supervisory body for the project execution, reporting and accountability before the General Assembly of partners. The ExC monitores strategic planning, work progress, identify and resolve problems or delays, ensure quality assurance and control project deliverables, budget, consistent and timely reporting.
Pr Antoine ITALIANO
Project Coordinator
Kathryn SCHUTTE
WP2 leader
Leader of the Histomics Solution
Alban BESSEDE
WP3 leader
Chief Executive Officer
Pr Hervé FRIDMAN
WP4 leader
Emeritus professor
Stephan SCHANN
WP5 leader
Vice President of Research
Dr Sophie POSTEL-VINAY
Gustave Roussy scientific leader
Medical oncologist and Physician scientist at the Drug Development Department
Dr Armelle DUFRESNE
Centre Léon Bérard scientific leader
Medical oncologist (Sarcoma and GIST)
Dr Helène ESPEROU
INSERM scientific leader
Head of Clinical Research Unit
